ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+12.16%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$188M
AUM Growth
+$188M
(+13%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
12.37%
Top 10 Holdings %
Top 10 Hldgs %
64.3%
Holding
38
New
9
Increased
8
Reduced
7
Closed
14
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$15.7M |
| 2 |
UnitedHealth
UNH
|
$13.5M |
| 3 |
AbbVie
ABBV
|
$12.8M |
| 4 |
IQVIA
IQV
|
$12.5M |
| 5 |
Centene
CNC
|
$12.2M |
Top Sells
| 1 |
Alkermes
ALKS
|
$11.5M |
| 2 |
Medtronic
MDT
|
$10.5M |
| 3 |
Insulet
PODD
|
$10.4M |
| 4 |
Hologic
HOLX
|
$10.3M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$10.2M |
Sector Composition
| 1 | Healthcare | 99.63% |
| 2 | Financials | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $15.7M | 8.34% | +177,741 | New | +$15.7M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.8M | 7.87% | 137,610 +112,661 | +452% | +$12.1M |
|
|
3
UnitedHealth
UNH
$281B
| $13.5M | 7.16% | +26,844 | New | +$13.5M |
|
|
4
AbbVie
ABBV
$372B
| $12.8M | 6.79% | +94,448 | New | +$12.8M |
|
|
5
IQVIA
IQV
$32.4B
| $12.5M | 6.64% | +44,314 | New | +$12.5M |
|
|
6
Centene
CNC
$14.3B
| $12.2M | 6.48% | +148,254 | New | +$12.2M |
|
|
BLU
7
DELISTED
BELLUS Health Inc.
BLU
| $10.3M | 5.47% | 1,280,757 +208,059 | +19% | +$1.67M |
|
8
Cytokinetics
CYTK
$4.23B
| $10.3M | 5.45% | 225,032 -21,304 | -9% | -$971K |
|
9
Johnson & Johnson
JNJ
$427B
| $9.54M | 5.06% | +55,755 | New | +$9.54M |
|
10
Natera
NTRA
$23.1B
| $9.5M | 5.04% | +101,674 | New | +$9.5M |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $8.28M | 4.39% | 716,709 +62,733 | +10% | +$725K |
|
12
argenx
ARGX
$43.6B
| $7.31M | 3.88% | +20,881 | New | +$7.31M |
|
13
Kura Oncology
KURA
$686M
| $7.03M | 3.73% | 502,275 +307,966 | +158% | +$4.31M |
|
14
Apellis Pharmaceuticals
APLS
$3.48B
| $6.59M | 3.5% | +139,445 | New | +$6.59M |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.44M | 3.42% | 43,876 +1,885 | +4% | +$277K |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.29M | 3.34% | 375,989 +20,593 | +6% | +$344K |
|
17
Quanterix
QTRX
$211M
| $6.07M | 3.22% | 143,204 -18,729 | -12% | -$794K |
|
18
iTeos Therapeutics
ITOS
$449M
| $4.88M | 2.59% | 104,755 +47,469 | +83% | +$2.21M |
|
|
DICE
19
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $4.69M | 2.49% | 185,201 -89,964 | -33% | -$2.28M |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $2.98M | 1.58% | 369,134 -105,234 | -22% | -$850K |
|
21
Aclaris Therapeutics
ACRS
$209M
| $2.89M | 1.53% | 198,493 -43,208 | -18% | -$628K |
|
22
PMV Pharmaceuticals
PMVP
$74.2M
| $2.26M | 1.2% | 97,680 -3,202 | -3% | -$74K |
|
|
RGLS
23
DELISTED
Regulus Therapeutics
RGLS
| $860K | 0.46% | 2,731,044 +1,329,553 | +95% | +$419K |
|
|
BLSA
24
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $699K | 0.37% | 71,372 -1,934 | -3% | -$18.9K |
|
|
25
Alkermes
ALKS
$4.78B
| – | – | -373,382 | Closed | -$11.5M |
|